A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

This Phase 1 study is testing IDE034 — a new bispecific antibody-drug conjugate that targets two proteins found on cancer cells (B7-H3 and PTK7) — in adults with advanced or metastatic solid tumors including lung cancer, esophageal cancer, endometrial cancer, ovarian cancer, head and neck cancer, triple-negative breast cancer, colorectal cancer, and prostate cancer. The study starts with dose escalation to find the safest and most effective dose, then expands to test that dose in larger groups of specific cancer types. Adults 18 and older with measurable disease expressing both target proteins, good performance status, and who have received at least one prior therapy are eligible, while those with active brain metastases, severe cardiac or lung disease, or prior treatment with similar drugs are excluded. Participants will receive IDE034 intravenously at scheduled intervals and attend regular visits for safety monitoring and tumor response assessments. This summary was prepared to help patients understand the study in plain language.